Preprint
Review

This version is not peer-reviewed.

The Probe-lem Solved? The Road Toward an In Vivo, ATP-competitive CK2 Chemical Probe

Submitted:

17 November 2026

Posted:

18 November 2026

You are already at the latest version

Abstract
The complexity of casein kinase 2 (CK2/CSNK2; encoded by CSNK2A1, CSNK2A2, and CSNK2B) and its regulatory roles across numerous cellular pathways both underscores its broad therapeutic potential and complicates efforts to define the contexts in which CK2 inhibition may be clinically beneficial. Accordingly, the development of high-quality chemical probes remains essential for elucidating CK2 biology. Since 2023, substantial progress has been made toward identifying potent, selective, and pharmacologically relevant CK2 inhibitors. Here, we summarize recent advances in ATP-competitive CK2 inhibitor development, with particular emphasis on cellular activity, kinome-wide selectivity, pharmacokinetic properties, and suitability for in vivo studies. We discuss the optimization of established monovalent chemotypes, including the pyrazolo[1,5-a]pyrimidine scaffold exemplified by SGC-CK2-1, as well as emerging scaffolds and bivalent inhibitor derivatives. Among the inhibitors discussed, APL-5125 has notably progressed toward an in vivo CK2 probe based on its single-digit nanomolar potency, excellent kinome-wide selectivity, and favorable in vivo properties that have supported its advancement into Phase 1/2 clinical trials. We conclude by outlining future directions for probe-enabled interrogation of CK2 biology.
Keywords: 
;  ;  ;  ;  ;  ;  ;  
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.